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AbstrAct
Objective
To test the effectiveness of an integrated collaborative 
care model for people with depression and long term 
physical conditions.
Design
Cluster randomised controlled trial.
setting
36 general practices in the north west of England.
ParticiPants
387 patients with a record of diabetes or heart disease, 
or both, who had depressive symptoms (≥ 10 on 
patient health questionaire-9 (PHQ-9)) for at least two 
weeks. Mean age was 58.5 (SD 11.7). Participants 
reported a mean of 6.2 (SD 3.0) long term conditions 
other than diabetes or heart disease; 240 (62%) were 
men; 360 (90%) completed the trial.
interventiOns
Collaborative care included patient preference for 
behavioural activation, cognitive restructuring, graded 
exposure, and/or lifestyle advice, management of drug 
treatment, and prevention of relapse. Up to eight 
sessions of psychological treatment were delivered by 
specially trained psychological wellbeing practitioners 
employed by Improving Access to Psychological 
Therapy services in the English National Health 
Service; integration of care was enhanced by two 
treatment sessions delivered jointly with the practice 
nurse. Usual care was standard clinical practice 
provided by general practitioners and practice nurses.
Main OutcOMe Measures
The primary outcome was reduction in symptoms of 
depression on the self reported symptom checklist-13 
depression scale (SCL-D13) at four months after 
baseline assessment. Secondary outcomes included 
anxiety symptoms (generalised anxiety disorder 7), 
self management (health education impact 
questionnaire), disability (Sheehan disability scale), 
and global quality of life (WHOQOL-BREF).
results
19 general practices were randomised to collaborative 
care and 20 to usual care; three practices withdrew from 
the trial before patients were recruited. 191 patients 
were recruited from practices allocated to collaborative 
care, and 196 from practices allocated to usual care. 
After adjustment for baseline depression score, mean 
depressive scores were 0.23 SCL-D13 points lower (95% 
confidence interval −0.41 to −0.05) in the collaborative 
care arm, equal to an adjusted standardised effect size 
of 0.30. Patients in the intervention arm also reported 
being better self managers, rated their care as more 
patient centred, and were more satisfied with their care. 
There were no significant differences between groups in 
quality of life, disease specific quality of life, self 
efficacy, disability, and social support.
cOnclusiOns
Collaborative care that incorporates brief low intensity 
psychological therapy delivered in partnership with 
practice nurses in primary care can reduce depression 
and improve self management of chronic disease in 
people with mental and physical multimorbidity. The 
size of the treatment effects were modest and were 
less than the prespecified effect but were achieved in a 
trial run in routine settings with a deprived population 
with high levels of mental and physical multimorbidity.
trial registratiOn
ISRCTN80309252.
Introduction
Multimorbidity (the presence of two or more long term 
conditions) is prevalent,1 but the combination of a long 
WhAt Is AlreAdy knoWn on thIs topIc
Mental and physical multimorbidity is highly prevalent among primary care 
populations, but few interventions exist to improve mental health outcomes in this 
group
Collaborative care can improve depression in people with long term conditions, but 
most studies have been conducted in the United States, have recruited highly 
selected groups of patients without multimorbidity, and have used elite academic 
teams to deliver and supervise interventions
There is emerging evidence that collaborative care can translate to non-US settings, 
but there is uncertainty if these benefits are realisable in more routine settings and 
among patients with multimorbidity
WhAt thIs study Adds
Collaborative care that integrates brief low intensity psychological treatment within 
primary care can reduce depression and improve self management in the short term 
in people with multimorbidity, but the size of effects is modest
Mental health providers and practice nurses with limited experience of 
collaborative care can be trained to deliver high quality and patient centred 
integrated healthcare for people with mental and physical multimorbidity
The COINCIDE trial offers a template for how integrated collaborative care can be 
potentially implemented within the context of routine chronic disease management 
with only minimal changes to the organisation of primary care
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term condition and depression is associated with the 
greatest decrements in quality of life.2 Coexistence of 
depression is also associated with poorer outcome of 
physical disorders, increased mortality, and unsched-
uled care, with considerable cost implications: in the 
English National Health Service (NHS) the presence of 
depression increases the cost of care for patients with 
long term conditions by at least 45% or from £3910 to 
£5670 (€5181 to €7513; $5892 to $8544) a year.3–6
In 2005 the World Health Organization proposed 
that there can be “no health without mental health.”7 
And in 2011 the UK coalition government pledged par-
ity of esteem between physical and mental health to 
reduce inequities between physical and mental health 
services.8 That policy pledge included an explicit com-
mitment to improve the mental health of people with 
physical health problems. For people with long term 
conditions this can potentially be achieved by 
strengthening primary care to deliver mental health 
services within the context of management of chronic 
disease.9
Considerable gains have been made in primary care 
over recent years to improve access to and quality of 
depression care, with one promising intervention being 
“collaborative care,” a complex intervention that 
involves the use of a non-medical case manager work-
ing in conjunction with the patient’s physician (usually 
their primary care physician), often with the support 
and supervision of a mental health specialist (normally 
a psychiatrist or psychologist).10
A recent Cochrane review that included 79 ran-
domised controlled trials concluded that collaborative 
care is more effective than usual care for both depres-
sion and anxiety.11 Only nine trials included in this 
review, however, tested collaborative care models in 
which depression care was delivered to populations 
with recognised long term conditions; only one of these 
trials was conducted outside the United States, and this 
tested collaborative care for depression in patients with 
cancer in a specialist setting.12 In the UK, the National 
Institute for Health and Care Excellence (NICE) recom-
mends that people with long term conditions with mod-
erate to severe depression and associated functional 
impairment should be managed with collaborative 
care, but this guidance is based on a secondary analysis 
of a weak evidence base.13 Furthermore, there is consid-
erable uncertainty about the effectiveness of integrated 
collaborative care models for managing depression in 
patients with multimorbidity in primary care settings 
that resemble routine care—trials to date have been run 
in academic primary care with populations without 
multimorbidity.
We tested the effectiveness of an integrated collabo-
rative care model for people with depression and long 
term conditions in which interventions were delivered 
by existing providers and patients had the freedom to 
choose various psychological treatments and/or drugs 
for their depression. We targeted patients with depres-
sion and diabetes and/or heart disease as exemplar 
cases. These patients are known to have increased 
symptoms of depression and high levels of medical 
comorbidity and thus serve as a test case for the inter-
vention in populations with multimorbidity.
Methods
study design and participants
The Collaborative Interventions for Circulation and 
Depression (COINCIDE) trial was conducted by a multi-
disciplinary team as part of the Greater Manchester Col-
laboration for Leadership in Applied Health Research 
and Care (CLAHRC). CLAHRCs are innovative research 
programmes funded by the UK National Institute for 
Health Research that support evaluations of interven-
tions most likely to be rapidly adopted in routine clini-
cal practice. COINCIDE was a pragmatic practice level 
cluster randomised controlled trial with two parallel 
groups. The trial protocol has been previously pub-
lished14 and updated.15
This trial was conducted in the English NHS in 
non-academic primary care general practices. We used 
a cluster design to avoid contamination of participants 
in the control group. General practices that held elec-
tronic registers of patients with diabetes and/or coro-
nary heart disease were recruited across the north west 
of England between January and November 2012. Eligi-
ble patients were those with a record of diabetes and/or 
coronary heart disease registered at one of the partici-
pating practices who also had depressive symptoms 
(score ≥ 10 on the nine item patient health question-
naire (PHQ-9))16 for at least two weeks. Before postal 
invitations were sent, general practitioners checked the 
disease registers to exclude ineligible patients (aged 
under 18, recently deceased, no diabetes or coronary 
heart disease, or on the palliative care register). We 
excluded patients with psychosis or type I or type II 
bipolar disorder; those who were actively suicidal; 
those in receipt of services for substance misuse; or 
those in receipt of psychological therapy for depression 
from a mental health service.
Staff from the National Institute for Health Mental 
Health Research Network searched electronic records 
from participating general practices for eligible 
patients. Patients who met the eligibility criteria 
received a postal invitation, followed by a reminder let-
ter three weeks later; non-responders to the reminder 
postal invitation were telephoned. To enhance recruit-
ment of patients of South Asian origin an information 
flyer about the trial was included in Urdu and Gujarati; 
the information sheets and consent forms were also 
translated into Urdu and Gujarati. After the first postal 
invitation a researcher fluent in Urdu, Hindi, and Pun-
jabi telephoned eligible patients of South Asian origin 
who did not speak English to provide further informa-
tion about the study.
After receiving consent forms research staff screened 
patients for depressive symptoms over the telephone 
using the PHQ-916 and confirmed eligibility. Patients 
who scored ≥ 10 on the PHQ-9 were then visited by a 
researcher two weeks later and asked to complete a 
 second PHQ-9. If patients also scored ≥ 10 on the PHQ-9 
at the face-to-face visit they were invited to complete 
baseline assessments.
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randomisation and masking
General practices were randomised as they were 
recruited by using a central randomisation service pro-
vided by the clinical trials unit at the Christie NHS 
Foundation Trust, Manchester. Allocation of practices 
(other than the first six, which were allocated 1:1 at ran-
dom) was by minimisation. This technique ensures 
“treatment groups that are very closely similar for sev-
eral variables” even in small samples.17 We used only 
two practice level variables (index of multiple depriva-
tion18 and list size) and incorporated a random element 
into this process by which practices were allocated to 
the trial arm that minimised the imbalance between 
characteristics with a probability weighting of 0.8.19 The 
allocation sequence was concealed from general prac-
tice staff and from all research staff, except the trial 
manager, the principal investigator, and the senior 
investigator with clinical supervisory responsibilities. 
Patients remained unaware of treatment allocation 
throughout the telephone screening and the baseline 
assessment appointments with research staff. Research-
ers who collected outcome data remained blinded to 
treatment allocation throughout the course of the trial. 
Because this trial used face-to-face psychological treat-
ments it was not possible to maintain the blinding of 
participants beyond baseline or to blind the health pro-
fessionals delivering the intervention.
intervention and comparators
Collaborative care
Over three months, participants in the collaborative 
care arm received up to eight face-to-face sessions of 
brief psychological therapy delivered by a case man-
ager who were “psychological wellbeing practitioners” 
employed by Improving Access to Psychological Thera-
pies services in the English NHS. These services offer 
evidence based psychological treatments for people 
aged over 16, with no upper age limit, in accordance 
with stepped care treatment models recommended by 
NICE.20 Eighteen psychological wellbeing practitioners 
were involved in delivery of the intervention. Twelve of 
them were women; their mean age was 35 (SD 9.3); and 
they had a mean of 3.9 (SD 1.7) years of service.
The first treatment session aimed to be completed 
within 45 minutes during which the psychological well-
being practitioner used a structured patient centred 
interview21 to gather information about the nature of 
the patient’s key problems, including their experience 
of the autonomic, behavioural, and cognitive symptoms 
associated with low mood and anxiety (the ABC 
model),22 any modifying factors, and the impact of 
these symptoms, including level of risk. The link 
between the patient’s mood and management of their 
diabetes and/or heart disease was explored, and they 
were introduced to the standardised treatment manual 
and workbook (see appendix 1 and 2) to help develop a 
main problem statement and personalised goals. Sub-
sequent sessions lasted for 30–40 minutes. Working 
with their psychological wellbeing practitioner, partic-
ipants in the collaborative care arm chose to engage in 
behavioural activation, graded exposure, cognitive 
restructuring, and/or lifestyle changes. Treatments took 
place at the participant’s general practice clinic or at 
Improving Access to Psychological Therapies business 
premises.
To better achieve integrated care, a 10 minute collab-
orative meeting (by telephone or in person) between the 
patient and the psychological wellbeing practitioner 
and a practice nurse from the patient’s general practice 
was scheduled to take place at the end of the second 
and eighth sessions. Psychological wellbeing practi-
tioners were guided by a manual to run these joint ses-
sions (see appendix 3). These collaborative meetings 
focused on ensuring that psychological treatments did 
not complicate management of physical health and 
patient safety, reviewing patients’ progress with their 
problem statement and goals, reviewing relevant phys-
ical and mental health outcomes (such as depression, 
anxiety, diet, exercise), and planning future care. Psy-
chological wellbeing practitioners also worked collabo-
ratively with the patient and practice nurse to check 
that patients adhered to antidepressants as prescribed, 
dealt with concerns about side effects, and helped to 
arrange drug reviews with the general practitioner if 
necessary. In keeping with routine management of 
patients within Improving Access to Psychological 
Therapies services, psychological wellbeing practi-
tioners monitored patients’ progress at each session, 
and delivery of care was structured in accordance with 
established stepped care protocols.23
Psychological wellbeing practitioners were trained in 
the COINCIDE collaborative care model over five days 
by a multidisciplinary team of psychological therapists, 
an academic general practitioner with special interests 
in mental health, and a primary care psychiatrist. Cul-
tural competency training was delivered by a psychia-
trist with special interests in translation of guided self 
help materials for people of South Asian origin. The 
training programme was piloted as part of a separate 
roll out of collaborative care in another region of the 
NHS24 and included sessions about diabetes and heart 
disease along with live and video demonstrations of 
each treatment session using simulated patients. The 
final training session focused on strategies for main-
taining health and relapse prevention, effective liaison, 
supervision, and monitoring.
Practice nurses attended a half day workshop, where 
they met the psychological wellbeing practitioners 
tasked to work in their general practice and were intro-
duced to the COINCIDE care model with an emphasis on 
effective liaison and delivering integrated physical and 
mental health care.
Psychological wellbeing practitioners received one 
hour of weekly individual supervision by an experi-
enced psychological therapist within their service. 
New patients, patients at risk of self harm or harming 
others, poorly responding patients, and patients who 
did not attend were discussed at weekly supervision, 
and every case was reviewed during monthly case 
management supervision.25 Supervisors could consult 
the trial clinical team about drug management. The 
COINCIDE team psychiatrist also visited Improving 
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Access to Psychological Therapies teams to discuss 
how psychological wellbeing practitioners could work 
flexibly to respond to problems raised by patients—for 
example, by using the collaborative care approach to 
manage symptoms of anxiety or to manage depressive 
symptoms that were not linked to their long term con-
dition. The trial psychiatrist also offered supervisors 
the option of telephone support.
Usual care
All participants received care as usual from their general 
practitioner, which could include referral for psycholog-
ical therapy (including therapy provided by Improving 
Access to Psychological Therapies) and/or prescription 
of antidepressants. Psychological wellbeing practi-
tioners who had been trained in the COINCIDE care 
model were restricted from working with patients allo-
cated to control general practices.
Outcomes
All outcomes were collected at the individual partici-
pant level. Participants were followed up initially at six 
months. After a change in the protocol (see statistical 
analysis) participants were subsequently followed up at 
four months. To maximise retention, follow-up assess-
ments were conducted when possible in person, 
although those who declined a visit were asked to com-
plete the primary outcome measure over the telephone.
The primary outcome was the difference in the mean 
score on the 13 depression items of the symptom check 
list-90 (SCL-D13) four months after randomisation.26 The 
SCL-D13 has 13 items rated from 0–4, and the patients’ 
overall score on each item is an average of these ratings; 
higher scores indicate more severe depression. Second-
ary mental health outcomes were depression and anxi-
ety measured with assessments used routinely in 
Improving Access to Psychological Therapies (PHQ-9 
and generalised anxiety disorder-7 (GAD-7)27), and social 
support (ENRICHD social support inventory28). Physical 
health outcomes were global quality of life (WHO-
QOL-BREF29), disease specific quality of life (diabetes 
quality of life30 and Seattle angina questionnaire31), and 
disability (Sheehan disability scale (SDS)32). To assess 
change in behaviours and perceptions about managing 
long term conditions we assessed self management 
(health education impact questionnaire (heiQ)33), self 
efficacy,34 and illness beliefs (multimorbidity illness per-
ceptions scale35). Process measures collected only at fol-
low-up were patient centredness and care experience 
(patient assessment of chronic illness care (PACIC)36), 
and satisfaction with care (client satisfaction question-
naire (CSQ)37). The PACIC questionnaire is widely seen 
as a valid patient reported assessment of the delivery of 
high quality care for long term conditions and higher 
scores confirm hypothesised associations between 
shared decision making and assessments of quality of 
care and patient satisfaction.38
All secondary outcomes reported here were prespec-
ified in the trial protocol but not prospectively regis-
tered in the trial register because of an administrative 
error on the part of the trial team.
sample size
We powered the trial to have 80% power (α = 0.05; 
intraclass correlation coefficient 0.06) to detect a differ-
ence between groups on the primary outcome at fol-
low-up equivalent to a standardised effect size of 0.4, 
for which we required 15 practices per arm and 15 
patients per cluster (n = 450), allowing for 20% attri-
tion. Our forecast was principally based on the findings 
of a pilot study of collaborative care in UK primary care 
that reported an effect size of 0.63 (95% confidence 
interval 0.08 to 1.07)39 and a subgroup analysis of 10 col-
laborative care trials that recruited patients with long 
term conditions (effect size −0.30, 95% confidence 
interval −0.39 to −0.21).13 We anticipated that the 
achievable effect size in populations with multimorbid-
ity would be 0.4, which is a little under the average of 
these two previously published effect sizes.
Average recruitment in the first 11 practices was less 
than 15 patients per practice. We therefore increased the 
total number of clusters from 30 to 36, with a target of 10 
patients per practice, to give 79% power to detect an 
effect of 0.4 under the same assumptions. The revised 
target sample was therefore 360 patients. To ensure that 
we recruited patients from the additional practices 
within the lifetime of the trial we reduced follow-up 
from six to four months. Changes to the protocol were 
made in agreement with the trial steering committee 
and published.15
statistical analysis
We undertook intention to treat analyses for all clinical 
outcomes, reported in accordance with the Consoli-
dated Standards of Reporting Trials guidelines exten-
sion for cluster trials.40 All analyses were undertaken in 
Stata 13, after a predefined analysis plan was shared 
with the data monitoring and ethics committee. We 
analysed outcomes at the end of follow-up using multi-
ple linear regression with robust standard errors to 
account for the clustering of patients within practices.41 
We controlled for baseline values of each outcome, 
patient age, sex, area deprivation (based on residential 
postcode), level of limitation of daily activities because 
of comorbidities,42 and use of antidepressants or anti-
anxiety drugs (currently, previously, never); and at the 
practice level for the design (minimisation) factors of 
list size and area deprivation. Multiple imputation was 
used to estimate missing scale scores and other data 
values at both baseline and follow-up. It was based on 
chained equations with all primary and secondary out-
comes (at both baseline and follow-up), patient demo-
graphics (age, sex, education), diagnoses (diabetes 
and/or heart disease), activity limitation, practice size, 
and deprivation. We used 10 multiple imputation sets to 
provide stability of results.43
We used multiple imputation for the main analysis 
because this generally provides less biased estimates of 
effect compared with a complete cases analysis.44 We 
ran two types of sensitivity analyses. To assess sensitiv-
ity of the results to multiple imputation we conducted a 
second analysis on complete cases that included all 
the  same covariates as the main analysis. A further 
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 sensitivity analysis was undertaken, adding in a vari-
able for length of follow-up, to determine if differential 
follow-up affected inferences. In all analyses we con-
trolled for baseline values and clustering. We also 
report a further post hoc sensitivity analysis for the 
 primary outcome using a restricted covariate set com-
prising the baseline outcome values and design factors 
(list size and area deprivation). 
For outcomes with skewness outside the range (−1.5 
to 1.5) or kurtosis outside the range (1.5 to 4.5), we used 
standard errors based on 1000 bootstrapped samples to 
derive confidence intervals and P values. To ease inter-
pretation and to allow comparison with published stud-
ies, we estimated standard effect sizes as the difference 
in follow-up means divided by the pooled baseline stan-
dard deviation for all participants.
results
Participant flow and retention
We invited 459 practices and allocated 39 of them, 19 to 
collaborative care and 20 to usual care; three withdrew 
before patients were invited to take part. Table 1 shows 
characteristics of included clusters. Practices in the two 
arms were similar in all characteristics. Mental Health 
Research Network staff ran the first electronic searches 
for patients on 10 April 2012 and sent the last mail out on 
18 March 2013. The first participant was recruited on 18 
May 2012, and the last participant was recruited on 31 
May 2013. A mean of 10.7 (SD 6.2, range 2–22) participants 
were recruited from each of the 36 practices. We identified 
387 patients with depression and heart disease and/or 
diabetes and invited them to a baseline assessment 
(figure). Follow-up data on 350 (90%) participants were 
collected between 18 November 2012 and 4 October 2013.
baseline characteristics of participants
Three quarters of participants (295/387; 76%) were 
recruited from practices from moderately and heavily 
deprived areas, over half of whom (125; 54%) came 
from areas ranked as highly deprived (index of multi-
ple deprivation score ≥ 30). Most (245; 64%) met crite-
ria for moderately severe or severe depression, and 290 
(75%) met criteria for anxiety. Participants had a mean 
of 6.2 (SD 3.0) medical conditions in addition to either 
diabetes or coronary heart disease; 15% of participants 
had a diagnosis of both diabetes and coronary heart 
disease. Just under two thirds (62%) of participants 
were men, and the mean age was 58.5 (SD 11.7); only 96 
(25%) participants were in paid employment. Half of 
participants were prescribed antidepressants or anti-
anxiety drugs at baseline (Table 2). Patients in the two 
arms were similar in all respects, except that a higher 
percentage of usual care arm patients were in large 
practices (106 (54%) v 70 (37%)).
Delivery of the intervention
Psychological wellbeing practitioners each treated a 
mean of nine patients (SD 6.3, range 1–21). Patients 
received a mean of 4.4 sessions (SD 3.3, range 0–14); 24 
(12.6%) patients received eight treatment sessions and 
67 (35%) received at least six sessions. Twenty two 
(11%) participants in the collaborative care arm did not 
attend any treatment sessions and disengaged immedi-
ately after referral; 42 (22%) participants did not attend 
any scheduled treatment session, and 30 (16%) did not 
attend two or more scheduled treatment sessions. 
Allocated to usual care (n=20; 51%)Allocated to collaborative care (n=19; 49%)
Allocated to usual care (n=19; 53%)Allocated to collaborative care (n=17; 47%)
GP surgeries recruited (n=39)
Patients identied on disease registers (n=18 400):
  Excluded by clinical sta­ (n=3557; 19%)
  Contacted (n=14 843; 81%)
Opted into screening interviews (n=797; 5.4%)Opted into screening interviews (n=805; 5.4%)
Received collaborative care (n=191; 23.7%)
Withdrew (n=3; 7.7%)
Excluded (n=614):
  <10 on PHQ-9 (n=477; 59.2%)
  Declined (n=52; 6.4%)
  Ineligible (n=47; 5.8%)
  Unable to contact (n=38; 4.7%)
Followed-up (n=170; 89.0%)
Completed SCL-D13 (n=170)
Lost to follow-up (n=21; 11.0%)
Followed-up (n=180; 91.8%)
Completed SCL-D13 (n=180)
Lost to follow-up (n=13; 6.6%)
Died (n=3; 1.6%)
Received usual care (n=196; 24.5%)
Excluded (n=591):
  <10 on PHQ-9 (n=440; 55.2%)
  Declined (n=56; 7.0%)
  Ineligible (n=61; 7.6%)
  Unable to contact (n=34; 4.2%)
cOnsOrt flow diagram of recruitment of general practices and patients in study of 
integrated primary care for patients with mental and physical multimorbidity. at four 
months, 106 (62.4%) participants assigned to collaborative care and 161 (89.4%) assigned 
to usual care were followed up. at six months 64 (37.6%) participants assigned to 
collaborative care and 19 (10.6%) assigned to usual care were followed up
table 1 | cluster (general practices) characteristics of practices included in study of 
integrated primary care for patients with mental and physical multimorbidity. Figures 
are numbers or numbers (percentage) of practices unless specified otherwise
intervention 
(n = 17)
control 
(n = 19)
Area:
 Merseyside 7 2
 Greater Manchester 8 11
 East Lancashire 2 6
List size:
 Small < 4500 9 (53) 8 (42)
 Medium 4500–7500 4 (23) 5 (26)
 Large > 7500 4 (23) 6 (31)
Deprivation:
 Affluent 6 (35) 6 (31)
 Moderately deprived 5 (29) 7 (37)
 Heavily deprived 6 (35) 6 (31)
Patients on quality and outcomes framework disease registers:
 Coronary heart disease 3521 4694
 Diabetes 4367 5818
Mean participants/practice (SD) with diabetes 6.2 (3.5) 5.6 (3.4)
Mean participants/practice (SD) with coronary heart disease 3.7 (2.1) 3.7 (2.6)
Mean participants/practice (SD) with both 2.4 (1.1) 1.7 (1.6)
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 Participants who disengaged immediately from therapy 
or did not attend scheduled therapy sessions were still 
followed-up unless they withdrew from the trial. Fifty 
(26%) participants attended one joint integrated care 
session; 46 (24%) attended two sessions; 95 (50%) did 
not attend any session. The mean length of mental 
health treatment sessions was 27 (SD 29.7) minutes, and 
the mean length of integrated care sessions was 19.7 (SD 
11.9) minutes. There was a small but non-significant 
increase in use of antidepressants during the trial (6% 
increase in the collaborative care group, 7% in the usual 
care group).
Primary outcome
We collected primary outcome data for 350 participants. 
At the end of follow-up depression scores (on the SCL-
D13) declined in both groups, but the decline was 
greater in the collaborative care arm. The mean depres-
sion score at follow-up was 0.23 points lower (95% con-
fidence interval −0.41 to −0.05) in participants who 
received collaborative care compared with those who 
received usual care, after adjustment for baseline 
depression and minimisation variables (Table 3). The 
samples sizes, group means, and standard deviations 
in Table 3 are based on participants who provided data 
at follow-up, but the estimated difference in means and 
95% confidence intervals are taken from the intention 
to treat analysis (that is, using multiple imputation for 
missing baseline and follow-up data points). The intra-
cluster coefficient for the primary outcome was 0.03 
(0 to 0.10). The difference found between the groups is 
equal to a standardised mean difference of −0.30 (−0.54 
to −0.07), with baseline standard deviation for SCL-D13 
(pooled).
secondary outcomes
The benefits of the intervention extended to some but 
not all secondary outcomes. Participants in the collab-
orative care arm reported fewer symptoms of anxiety at 
follow-up compared with those in the usual care arm, 
equating to a reduction of 1.45 points (95% confidence 
interval −2.45 to −0.56) on the generalised anxiety disor-
der scale (GAD-7), equivalent to a standardised mean 
difference of −0.28 (−0.47 to −0.09). Core aspects of self 
management on five of the eight domains of the health 
education impact questionnaire (heiQ) significantly 
improved in patients in the collaborative care arm 
(Table 3).
We observed no significant differences between 
groups for disability, self efficacy, illness perceptions, 
and global quality of life (Table 3) or for disease specific 
quality of life (Table 4).
Process data showed that participants in the collabo-
rative care arm rated the delivery and experience of care 
as more patient centred. Patients’ scores on all five sub-
scales of the patient assessment of chronic illness care 
(PACIC) were higher in the collaborative care arm than 
in the usual care arm, as was the total score on this 
scale (2.37 (SD 1.0) v 1.98 (SD 0.9)), equivalent to an 
unadjusted standardised mean difference of 0.39. Based 
on total scores on the client satisfaction questionnaire 
(CSQ) participants in the collaborative care arm were 
also more satisfied with their care at follow-up com-
pared with usual care (2.90 (SD 0.6) v 2.62 (SD 0.6)), 
equivalent to an unadjusted standardised mean differ-
ence of 0.53 (Table 5).
Missing data and sensitivity analyses
Telephone interviews were used to collect primary out-
come data only among patients who declined a face to 
face follow-up assessment; 37 (9.6%) patients had miss-
ing data for the primary outcome. There was a higher 
percentage of missing data for secondary outcomes, but 
no scale had more than 20% missing data. We used 
multiple imputation for the main analysis to take 
account of this. Sensitivity analysis with a complete 
cases approach returned the same pattern of significant 
results, with the exception of self management 
behaviours measured on the health education impact 
questionnaire, with significant differences for two 
(instead of five) domains: self monitoring and health 
service navigation (Table 6). Departure from normality 
occurred only for self monitoring and insight on the 
table 2 | baseline characteristics of participants in study of integrated primary care for 
patients with mental and physical multimorbidity. Figures are numbers (percentage) of 
patients
intervention (n = 191) usual care (n = 196)
Practice deprivation:*
 Affluent 49 (26) 43 (22)
 Moderately deprived 80 (42) 90 (46)
 Heavily deprived 62 (32) 63 (32)
Practice size:*
 Small (< 4500) 60 (31) 49 (25)
 Medium (4500–7500) 61 (32) 41 (21)
 Large (> 7500) 70 (37) 106 (54)
Mean (SD) age (years) 57.9 (12.0) 59.2 (11.4)
Men 113 (59) 127 (65)
White 164 (86) 167 (85)
Mean (SD) deprivation (IMD score) 36.6 (21.3) 34.4 (18.5)
In owner occupied accommodation 115 (60) 122 (62)
In paid employment (full or part time) 49 (26) 47 (24)
Index medical condition by quality and outcomes framework register:
 Diabetes 106 (55) 101 (51)
 Coronary heart disease (CHD) 56 (29) 66 (34)
 Both 29 (15) 29 (15)
Mean (SD) No of long term conditions (other than 
diabetes or CHD)
6.0 (3.2) 6.5 (3.0)
Mean (SD) SCL-D-13 total (0–4) 2.36 (0.70) 2.33 (0.82)
Mean (SD) PHQ-9 total (0–27) 16.4 (4.2) 16.5 (4.1)
PHQ-9 score by symptom severity:
 10–14 (moderate) 68 (36) 73 (37)
 15–19 (moderate to severe) 79 (41) 76 (39)
 20–27 (severe) 44 (23) 47 (24)
Mean (SD) GAD-7 total (0–21) 12.3 (5.1) 11.9 (5.3)
GAD-7 score by symptom severity:
 0–4 (mild) 15 (7.9) 12 (6.1)
 5–9 (moderate) 42 (22.0) 61 (31.1)
 10–14 (moderate to severe) 72 (38.5) 56 (28.6)
 15–21 (severe) 62 (32.5) 67 (34.2)
Prescribed antidepressants 59 (31) 73 (37)
Prescribed antianxiety drugs 32 (17) 30 (15)
GAD = generalised anxiety disorder assessment; IMD = index of multiple deprivation; PHQ = patient health 
questionnaire; SCL-D13 = symptom checklist depression scale.
*Minimisation variables.
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health education impact questionnaire (heiQ) scale, 
when the central estimate and 95% confidence interval 
for both the multiple imputation and complete cases 
analyses were estimated via bootstrapping. A second 
sensitivity analysis, adjustment for length of follow-up 
(six v four months) had no important effect on the infer-
ences made in the main analysis.
The post hoc additional analysis of the self reported 
symptom checklist-13 depression scale (SCL-D13) with a 
restricted covariate set made only a small difference to 
the estimate of effect: 0.26 points (95% confidence 
interval −0.42 to −0.08), equivalent to a standardised 
mean difference of −0.34 (−0.56 to −0.11).
We received notification of four deaths unrelated to 
delivery of the intervention. Three deaths occurred in 
control practices; one death occurred in an intervention 
practice but after outcome data had been collected at 
follow up.
discussion
Collaborative care that integrated brief psychological 
interventions within the context of routine primary 
table 3 | intention to treat analyses of primary and secondary outcomes at four month follow-up in study of integrated primary care for patients with 
mental and physical multimorbidity
intervention usual care comparison
no of patients Mean (sD) no of patients Mean (sD)
adjusted difference in means 
(95% ci)*, P value effect size (95% ci)† 
intracluster 
coefficient
Primary outcome
SCL-D-13 (0–4) 170 1.76 (0.9) 180 2.02 (0.9) −0.23 (−0.41 to −0.05), 0.01 −0.30 (−0.54 to −0.07) 0.03
secondary outcomes
PHQ-9 (0–27) 157 11.3 (6.5) 168 13.1 (6.5) −1.2 (−2.37 to −0.03), 0.04 −0.29 (−0.57 to −0.01) 0.02
GAD-7 (0–21) 157 8.2 (5.8) 168 9.7 (5.9) −1.45 (−2.45 to −0.56), 0.006 −0.28 (−0.47 to −0.09) 0.00
ESSI (0–34) 155 3.29 (1.1) 165 3.4 (1.0) 0.01 (−0.19 to 0.22), 0.91 0.01 (−0.18 to 0.20) 0.07
Health education impact questionnaire (heiQ):
 Positive engagement 155 2.48 (1.3) 164 2.32 (1.4) 0.20 (−0.07 to 0.48), 0.14 0.16 (−0.06 to 0.39) 0.02
  Health directed 
behaviour
155 1.92 (1.8) 164 1.65 (1.5) 0.06 (−0.28 to 0.39), 0.72 0.04 (−0.18 to 0.26) 0.05
 Skill acquisition 153 2.76 (1.1) 163 2.52 (1.2) 0.26 (0.02 to 0.50), 0.04 0.25 (0.02 to 0.48) 0.04
 Constructive attitudes 155 2.83 (1.2) 165 2.64 (1.3) 0.31 (0.07 to 0.55), 0.01 0.25 (0.05 to 0.44) 0.02
 Self monitoring 155 3.65 (0.7) 165 3.32 (1.0) 0.31 (0.01 to 0.52),‡ 0.004 0.36 (0.11 to 0.60) 0.08
  Health service 
navigation
155 2.67 (1.0) 165 3.35 (1.2) 0.28 (0.03 to 0.53), 0.03 0.27 (0.03 to 0.52) 0.06
 Social integration 155 3.03 (1.3) 165 3.0 (1.4) −0.01 (−0.32 to 0.31), 0.10 –0.01 (−0.25 to 0.24) 0.08
 Emotional wellbeing 155 2.65 (1.3) 165 3.09 (1.2) −0.35 (−0.61 to −0.09), 0.01 −0.32 (−0.55 to −0.08) 0.05
MULTIPleS 151 2.1 (0.9) 165 2.28 (0.9) −0.14 (−0.34 to 0.06), 0.17 –0.18 (−0.43 to 0.08) 0.09
SDS (0–10) 153 5.73 (2.8) 163 5.83 (2.8) −0.27 (−0.75 to 0.20), 0.24 –0.11 (−0.29 to 0.08) 0.00
SEQ 155 5.72 (1.9) 166 5.54 (1.9) 0.21 (−0.15 to 0.58), 0.24 0.13 (−0.09 to 0.34) 0.02
WHOQOL-BREF 152 2.99 (0.6) 167 2.91 (0.6) 0.07 (−0.05 to 0.19), 0.26 0.13 (−0.10 to 0.36) 0.02
ESSI = Enrichd social support inventory; GAD = generalised anxiety disorder assessment; MULTIPleS = multimorbidity illness perception scales; SCL = symptom check list; SEQ = self efficacy 
questionnaire; SDS = Sheehan disability scale; SCL-D-13 = symptom checklist depression scale; WHOQOL-BREF = WHO quality of life measure.
*Analyses with multiple imputation for missing baseline and follow-up data points adjusted for baseline measures of outcome and minimisation variables (practice deprivation and practice size).
†Effect size based on pooled SD of baseline measures.
‡Estimated with bootstrapping. 
table 4 | intention to treat analyses of physical disease quality of life at follow-up in study of integrated primary care for patients with mental and 
physical multimorbidity
intervention usual care comparison
no of patients Mean (sD) no of patients Mean (sD)
adjusted difference in 
means (95% ci)*, P value effect size†
intracluster 
coefficient
Diabetes quality of life questionnaire
Satisfaction with treatment 111 54.6 (18.5) 118 53.7 (17.9) −0.72 (−4.18 to 2.74), 0.67 –0.04 0.03
Impact of treatment 112 65.3 (15.6) 120 63.9 (16.5) −0.99 (−3.91 to 1.94), 0.50 –0.07 0.07
Diabetes worries 26 70.2 (23.6) 31 76.1 (28.8) 3.52 (−15.13 to 22.17), 0.61 0.13 0.04
Social/vocational worries 97 66.0 (23.1) 111 63.7 (26.8) 0.52 (−5.40 to 6.43), 0.86 0.02 0.11
seattle angina questionnaire
Physical limitation 78 42.3 (28.5) 88 41.2 (28.9) 2.02 (−3.52 to 7.56), 0.46 0.08 0.00
Angina stability 77 52.6 (24.9) 85 47.9 (27.1) 5.32 (−2.15 to 12.80), 0.16 0.21 0.00
Angina frequency 81 70.5 (28.4) 83 68.0 (26.7) 2.30 (−3.05 to 7.64), 0.39 0.09 0.08
Treatment satisfaction 79 79.2 (17.3) 81 71.9 (24.5) 5.08 (−2.06 to 12.21), 0.16 0.27 0.05
Quality of life 79 51.6 (24.3) 82 46.0 (27.5) 5.50 (−1.47 to 12.47), 0.18 0.24 0.03
*Analyses with multiple imputation for missing baseline and follow-up data points adjusted for baseline measures of outcome and minimisation variables (practice deprivation and practice 
size).
†Effect size based on pooled SD of baseline measures.
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care management of long term conditions reduced 
depressive symptoms more than usual care in patients 
with multimorbidity. Participants in the collaborative 
care arm also reported significantly less anxiety at fol-
low-up. The observed treatment effect size (0.3) in our 
trial was modest and lower than the prespecified effect 
(0.4) but similar to that achieved in a previous UK 
study of collaborative care in adults without multimor-
bidity45 and comparable with the overall effect size for 
collaborative care of 0.29 reported in a Cochrane 
review in 2012.11 While these treatment effects for 
depression are modest, they were achieved in the 
 context of a pragmatic trial that included participants 
with considerable levels of mental and physical multi-
morbidity and high levels of socioeconomic depriva-
tion. In this sense our findings appeal to the need for 
research about how to potentially integrate mental 
and physical healthcare among disadvantaged popu-
lations with broader multimorbidity from deprived 
areas.46 47
The benefits of collaborative care extended beyond 
reductions in depressive and anxiety symptoms, with 
patients rating themselves as better self managers. Self 
management is increasingly seen as critical to the 
table 5 | Mean difference and effect sizes for process of care measures at follow-up in study of integrated primary care for patients with mental and 
physical multimorbidity
intervention usual care comparison
no of patients Mean (sD) no of patients Mean (sD) Difference in means (95% ci) effect size*
Patient assessment of chronic illness care (Pacic)
Patient activation 153 2.50 (1.4) 159 2.08 (1.2) 0.42 (0.13 to 0.71) 0.32
Delivery system design/decision support 153 2.71 (1.2) 159 2.29 (1.1) 0.42 (0.17 to 0.67) 0.36
Goal setting 153 2.18 (1.2) 158 1.77 (1.0) 0.41 (0.16 to 0.66) 0.37
Problem solving/contextual counselling 154 2.65 (1.2) 158 2.28 (1.2) 0.37 (0.10 to 0.64) 0.31
Follow-up/coordination 153 2.00 (0.9) 158 1.77 (1.0) 0.23 (−0.08 to 0.54) 0.16
Total score 155 2.37 (1.1) 163 1.98 (1.0) 0.39 (0.16 to 0.62) 0.37
client satisfaction questionnaire (csQ)
Quality of service 155 2.90 (0.9) 158 2.51 (1.0) 0.39 (0.18 to 0.60) 0.41
Kind of service you wanted 155 2.97 (0.8) 159 2.63 (0.9) 0.34 (0.15 to 0.53) 0.40
Satisfied with help 152 2.51 (1.0) 156 2.42 (1.0) 0.09 (−0.13 to 0.31) 0.09
Services helped 152 3.11 (0.8) 158 2.68 (0.9) 0.43 (0.24 to 0.62) 0.50
Satisfied overall 152 2.95 (0.9) 154 2.48 (0.8) 0.47 (0.28 to 0.66) 0.53
Come back to service 153 2.96 (0.8) 157 2.48 (0.8) 0.48 (0.30 to 0.60) 0.60
Total score 156 2.90 (0.6) 160 2.58 (0.6) 0.32 (0.19 to 0.45) 0.53
*Effect size based on pooled SD for collaborative care and usual care. 
table 6 | sensitivity analyses of primary and secondary outcomes at four month follow-up for complete cases in study of integrated primary care for 
patients with mental and physical multimorbidity
intervention usual care comparison
no of 
patients Mean (sD) no of patients Mean (sD)
adjusted difference in means 
(95% ci)*, P value effect size (95% ci)†
intracluster 
coefficient
Primary outcome
SCL-D-13 (0–4) 170 1.76 (0.9) 180 2.02 (0.9) −0.24 (−0.38 to −0.11), 0.001 −0.32 (−0.50 to −0.14) 0.03
secondary outcomes
PHQ-9 (0–27) 157 11.3 (6.5) 168 13.1 (6.5) −1.20 (−2.37 to −0.04), 0.04 −0.29 (−0.57 to −0.01) 0.02
GAD-7 (0–21) 157 8.2 (5.8) 168 9.7 (5.9) −1.61 (−2.57 to −0.66), 0.002 −0.31 (−0.49 to −0.09) 0.00
ESSI (0–34) 155 3.29 (1.1) 165 3.4 (1.0) 0.00 (−0.20 to 0.21), 0.96 0.00 (−0.19 to 0.19) 0.07
Health education impact questionnaire (heiQ):
 Positive engagement 155 2.48 (1.3) 164 2.32 (1.4) 0.12 (−0.11 to 0.36), 0.29 0.10 (−0.09 to 0.29) 0.02
 Health directed behaviour 155 1.92 (1.8) 164 1.65 (1.5) 0.04 (−0.30 to 0.37), 0.83 0.02 (−0.20 to 0.23) 0.05
 Skill acquisition 153 2.76 (1.1) 163 2.52 (1.2) 0.20 (−0.08 to 0.49), 0.16 0.19 (−0.08 to 0.47) 0.04
 Constructive attitudes 155 2.83 (1.2) 165 2.64 (1.3) 0.20 (−0.04 to 0.45), 0.10 0.17 (−0.03 to 0.04) 0.02
 Self monitoring 155 3.65 (0.7) 165 3.32 (1.0) 0.29 (0.08 to 0.49),‡ 0.007 0.33 (0.05 to 0.61) 0.08
 Health service navigation 155 2.67 (1.0) 165 3.35 (1.2) 0.29 (0.07 to 0.49), 0.01 0.28 (0.07 to 0.49) 0.06
 Social integration 155 3.03 (1.3) 165 3.0 (1.4) 0.00 (−0.30 to 0.29), 0.97 0.00 (−0.23 to 0.23) 0.08
 Emotional wellbeing 155 2.65 (1.3) 165 3.09 (1.2) 0.27 (−0.54 to 0.01), 0.06 −0.24 (−0.48 to 0.01) 0.05
MULTIPleS 151 2.1 (0.9) 165 2.28 (0.9) −0.10 (−0.28 to 0.07), 0.24 –0.13 (−0.36 to 0.09) 0.09
SDS (0–10) 153 54.3 (30.5) 163 55.3 (29.7) −0.10 (−0.55 to 0.34), 0.67 –0.04 (−0.22 to 0.14) 0.00
SEQ 155 5.72 (1.9) 166 5.54 (1.9) 0.08 (−0.30 to 0.50), 0.66 0.05 (−0.17 to 0.27) 0.02
WHOQOL-BREF 152 2.99 (0.6) 167 2.91 (0.6) 0.05 (−0.07 to 0.17), 0.38 0.10 (−0.13 to 0.32) 0.02
ESSI = Enrichd social support inventory; GAD = generalised anxiety disorder assessment; MULTIPleS = multimorbidity illness perception scales; SCL-D-13 = symptom checklist depression scale; 
SEQ = self efficacy questionnaire; SDS = Sheehan disability scale; WHOQOL-BREF = WHO quality of life measure.
*Adjusted for baseline measures of outcome and minimisation variables (practice deprivation and practice size). 
†Effect size based on pooled SD of baseline measure.
‡Estimated via bootstrapping.
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delivery of effective and efficient care for long term con-
ditions, but achieving effective self management is a 
considerable challenge in patients with multimorbidity. 
This in part stems from system level barriers because 
organisation of primary care is often poorly matched to 
the needs and experiences of patients living with mul-
timorbidity.48 There are two possible mechanisms that 
might explain why patients in our trial thought they 
could manage their symptoms more effectively: they 
were less depressed and thus more confident and 
engaged in their care, or the delivery of their care 
improved—for example, through provision of joint 
 therapy sessions—and this was highlighted by higher 
ratings for patient centredness in the collaborative 
care arm.
Improvements in self management behaviours are 
hypothesised to be antecedents to improvements in 
physical health,33 but we did not test this association in 
this trial. In the US the TEAMcare trial, which was a 
high intensity intervention for depression and diabetes 
or heart disease delivered in academic settings over 12 
months, observed significant improvements in social 
role disability and global quality of life.49 Large 
improvements in functional outcomes among 
depressed patients have typically been achieved in tri-
als that used more intensive interventions.50 Our trial 
offered a more limited less intensive intervention and 
did not see comparable improvements in disability or 
quality of life. Similarly, while the ENRICHD trial 
showed that high intensity therapies such as cognitive 
behavioural therapy can improve social support in 
patients with depression and heart disease, we did not 
observe such improvements.51 It is not clear what ingre-
dients of collaborative care are responsible for 
improvements in functional and social support out-
comes, but self efficacy has been proposed as a media-
tor that might strengthen depression interventions. 
TEAMcare did observe improvements in self efficacy 
whereas we did not.52
strengths and limitations
This was a large pragmatic trial conducted across a 
wide geographical area in the north west of England 
that included considerable socioeconomic deprivation 
and high densities of ethnic minorities. We recruited 
participants by systematically searching disease regis-
ters and screening for depression. There is evidence 
that this method of recruitment can identify patients 
who have additional capacity to benefit from collabora-
tive care.53 There was minimal attrition and no evidence 
that missing data or differential follow-up affected the 
results. Our findings, however, should be interpreted in 
the context of several limitations. Firstly, we could not 
recruit and assess participants before practices were 
randomised, leading to concerns that allocations might 
not have been concealed from practice staff and partic-
ipants. Because participants were recruited in a serial 
fashion from each practice, however, it was not practi-
cable to postpone allocation to treatment groups until 
all participants had been recruited. To aid allocation 
concealment, however, we used non-clinical staff to 
identify potential participants at each practice. Sec-
ondly, we were able to assess only the short term effec-
tiveness of collaborative care, and we do not know if the 
positive effects persist beyond four months. Our first 
goal, however, was to test the feasibility and effective-
ness of collaborative care in routine settings among 
under-served patients with long term conditions, and it 
is encouraging that we found positive effects for depres-
sion at four months. Additionally, four months has been 
used as the primary end point to test the effectiveness of 
collaborative care,45 and we would subscribe to the view 
this is the earliest time point at which we might expect 
to see a treatment effect for psychological therapies 
based on a behavioural modification framework.54 Fur-
thermore, while depression is for some people a long 
term problem, short term benefits are still likely to be 
important outcomes for patients. Thirdly, despite the 
use of self reported questionnaires and masking of 
research staff to allocation, all outcome data were col-
lected face to face at follow-up, and researchers might 
have been made aware of treatment allocations, leading 
to assessment bias. We did not formally test for this type 
of bias, which could have been done by interviewing 
researchers to determine whether they knew to which 
treatment group participants had been allocated. 
Fourthly, we collected only self reported data on the use 
of antidepressants. Future trials of this kind should 
make efforts to also collect data on changes to the type 
and dose of antidepressant so as to be able to judge 
whether patients who do not initially respond to treat-
ment are more likely to be switched to an alternative 
antidepressant in the context of collaborative care. 
Fifthly, we did not collect objective measures of physi-
cal functioning and were thus unable to assess the 
impact of collaborative care on both physical and men-
tal health. Unlike the TEAMcare55 trial, which used 
treat-to-target protocols for diabetes and heart disease, 
however, our intervention focused primarily on treating 
depression but also imparted skills and empowered 
patients to more effectively self manage their long term 
conditions. Finally, because we notified general practi-
tioners in both arms that participants met criteria for 
depression the effect of the intervention might have 
been reduced. This is unlikely given that screening for 
depression alone does not lead to changes in the man-
agement of depression.56
implications for practice, research, and policy
Our trial tested whether mental health workers with lim-
ited experience of collaborative care can be trained to 
routinely work alongside primary care nurses to deliver 
a simple and integrated care model for patients with 
high levels of mental and physical multimorbidity. The 
novel aspects of our trial have broad relevance for imple-
mentation of integrated care for mental-physical multi-
morbidity in routine settings. In the UK, the CADET trial 
has showed that the benefits of collaborative care for 
depression translate to settings outside the US.45 CADET 
did not specifically recruit patients with long term con-
ditions, however, and the relevance of findings in that 
trial for populations with multimorbidity are not known. 
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Landmark US trials of collaborative care for patients 
with depression and long term conditions similarly did 
not include patients with multimorbidity, and partici-
pants in these trials were less depressed at baseline than 
those in COINCIDE.55 57 This is also true of the TrueBlue58 
trial in Australia, which tested nurse led collaborative 
care for depression in patients with diabetes or heart 
disease. Half the patients in that trial had mild 
(sub-threshold) depression and significant treatment 
effects were reported only in a subgroup with moderate 
to severe depression. Such subgroup analyses are con-
troversial.59 Additionally, as with Teamcare, the course 
of treatment in TrueBlue lasted 12 months, reducing the 
relevance of these findings in primary care settings 
where the average course of brief psychological inter-
ventions is typically six sessions.60 By contrast, patients 
in COINCIDE were more deprived and more depressed 
and had higher levels of multimorbidity than compara-
ble collaborative care trials. This is true even of the 
IMPACT trial,61 which tested collaborative care for 
depression in older adults, lending further support to 
the finding that younger adults with depression from 
deprived areas have higher rates of multimorbidity than 
older populations.1
Compared with previous collaborative care trials, 
COINCIDE tested a broader range of psychological 
 treatments (that is, behavioural activation, cognitive 
restructuring, graded exposure, and lifestyle approaches, 
with the option to stay or start taking antidepressants), 
and they were tailored to meet the needs of patients 
with long term conditions, thus enhancing the integra-
tion of physical and mental healthcare. Half the 
patients in COINCIDE attended a joint meeting with 
their practice nurse and psychological therapist, and 
this level of integration between mental and physical 
healthcare providers in primary care is unprecedented. 
It could equally be argued, however, that the level of 
collaboration between psychological wellbeing practi-
tioners and nurses was minimal, suggesting that the 
positive effects for depression were attributable to the 
presence of the psychological wellbeing practitioner 
and not the collaborative framework. There is good evi-
dence that collaborative care that includes psychologi-
cal therapy with or without drugs is more effective than 
collaborative care that includes only drugs, and our 
trial would support this finding.53 We do not, however, 
have definitive evidence about the mechanisms that led 
to improved depression outcomes in our trial, and 
future research is needed that can model the effects of 
both intervention and individual patient level modera-
tors on treatment outcomes.
Previous collaborative care trials for depression and 
long term conditions have also relied on input from 
academic supervisors, whereas in COINCIDE thera-
pists were supervised by existing providers. In this 
sense the COINCIDE trial is a test case of how a brief 
and integrated collaborative care model can be rolled 
out at a pace and scale within the context of chronic 
disease management by using existing providers and 
without greatly altering arrangements for clinical 
supervision. Proof of this is evidenced by the uptake of 
the COINCIDE care model among Improving Access to 
Psychological Therapies services in England as part of 
a phased National Institute for Health Research 
funded roll out and evaluation of collaborative care for 
people with long term conditions and common mental 
health problems.62 Following a commitment to extend 
Improving Access to Psychological Therapies to meet 
the needs of patients with long term conditions, this 
roll out involves the COINCIDE team training the psy-
chological wellbeing practitioner workforce to work 
collaboratively in primary care to deliver low intensity 
psychological treatments to patients with a wide range 
of long term conditions. Long term implementation is 
underpinned by delivery of a “train the trainer” pro-
gramme, in which clinical champions from participat-
ing Improving Access to Psychological Therapies 
services will take on responsibility for future training 
of psychological wellbeing practitioners to work with 
the COINCIDE care model. This initiative bridges the 
gap from evidence to practice through effective part-
nership working between research leaders, service 
providers, and commissioners to meet the needs of 
complex patients with multimorbidity.
conclusions
This trial answers the call to better understand how to 
integrate mental healthcare in general healthcare 
through developing innovative care models and 
strengthening close links to specialist services.63 For 
the first time we have shown that patients with high 
levels of mental and physical multimorbidity can gain 
modest but important benefits from brief low intensity 
psychological interventions delivered in partnership 
with practice nurses, rather than waiting to be stepped 
up to more intensive and less available treatments, as 
currently recommended in England by the NICE.20 As 
has been shown in cancer settings,64 patients with 
medical comorbidities benefit more if their depression 
is proactively managed with an integrated collabora-
tive care approach. It is imperative for the health and 
wellbeing of people with mental and physical multi-
morbidity that future research focuses on how best 
to translate such integrated care models into routine 
primary care.
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